Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 24554753)

1.

Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay.

Munson E, Schroeder ER, Ross KC, Yauck C, Bieganski T, Amrhein RD, Napierala M, Harkins AL.

J Clin Microbiol. 2014 May;52(5):1448-52. doi: 10.1128/JCM.03624-13. Epub 2014 Feb 19.

2.

Stability of human papillomavirus (HPV) in cervical ThinPrep specimens previously lysed with glacial acetic acid: effect on cobas 4800 HPV test performance.

McMenamin M, McKenna M.

Cancer Cytopathol. 2014 Apr;122(4):250-6. doi: 10.1002/cncy.21377. Epub 2013 Dec 3.

PMID:
24302639
3.

Effect of glacial acetic acid treatment of liquid-based cytology collections on performance of Cervista HPV HR for detection of high-risk human papillomavirus.

Munson E, Du Chateau BK, Nelson BE, Griep J, Czarnecka J, Amrhein RD, Schroeder ER.

J Clin Microbiol. 2012 Jun;50(6):2129-31. doi: 10.1128/JCM.06719-11. Epub 2012 Mar 21.

4.

Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus.

Moore C, Cuschieri K, McQueen F, Duvall E, Graham C, Cubie HA.

Cytopathology. 2013 Oct;24(5):314-20. doi: 10.1111/cyt.12046. Epub 2013 Feb 5.

PMID:
23379748
5.

Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens.

Nolte FS, Ribeiro-Nesbitt DG.

Am J Clin Pathol. 2014 Oct;142(4):561-6. doi: 10.1309/AJCP1REBI2UVBHMX.

PMID:
25239425
7.

Effect of glacial acetic acid treatment of cervical ThinPrep specimens on HPV DNA detection with the cobas 4800 HPV test.

McMenamin M, McKenna M.

Cytopathology. 2013 Oct;24(5):321-6. doi: 10.1111/cyt.12052. Epub 2013 Feb 27.

PMID:
23445358
8.

Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.

Zhao J, Zhang X, Ma J, Liu G, Yao D, Zhang W, Wang J, Wei L, Zhao Y, Zeng Y, Liao Q.

J Low Genit Tract Dis. 2012 Oct;16(4):358-63.

PMID:
23023138
10.

Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid.

Munson E, Kroeger L, Balzer S, Amrhein R, Munson KL, Napierala M, Hudspeth R, Dillon PJ.

J Clin Microbiol. 2014 Jan;52(1):331-4. doi: 10.1128/JCM.03066-13. Epub 2013 Nov 6.

11.

Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.

Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.

Int J Gynecol Cancer. 2013 Mar;23(3):513-8. doi: 10.1097/IGC.0b013e318280f3bc.

PMID:
23334437
12.

Comparative analysis of a liquid-based Pap test and concurrent HPV DNA assay of residual samples. A study of 608 cases.

Hong IS, Marshalleck J, Williams RH, Gaiter TE, Mielzynska-Lohnas I, Kim K.

Acta Cytol. 2002 Sep-Oct;46(5):828-34.

PMID:
12365215
13.

Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.

Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N.

J Clin Microbiol. 2011 Mar;49(3):1071-6. doi: 10.1128/JCM.01674-10. Epub 2010 Dec 29.

14.

Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.

Zhao FH, Hu SY, Bian JJ, Liu B, Peck RB, Bao YP, Pan QJ, Frappart L, Sellors J, Qiao YL.

Cancer Cytopathol. 2011 Dec 25;119(6):387-94. doi: 10.1002/cncy.20177. Epub 2011 Jul 19.

PMID:
21774094
15.

Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.

Tao K, Yang J, Yang H, Guo ZH, Hu YM, Tan ZY, Zhang F, Duan JL.

Diagn Cytopathol. 2014 Mar;42(3):213-7. doi: 10.1002/dc.23025. Epub 2013 Aug 1.

PMID:
23904341
16.

Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA.

Ginocchio CC, Barth D, Zhang F.

J Clin Microbiol. 2008 May;46(5):1641-6. doi: 10.1128/JCM.01824-07. Epub 2008 Mar 26.

17.

The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.

Heideman DA, Hesselink AT, van Kemenade FJ, Iftner T, Berkhof J, Topal F, Agard D, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2013 Nov;51(11):3653-7. doi: 10.1128/JCM.01517-13. Epub 2013 Aug 28.

18.

Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.

Youens KE, Hosler GA, Washington PJ, Jenevein EP, Murphy KM.

J Mol Diagn. 2011 Mar;13(2):160-6. doi: 10.1016/j.jmoldx.2010.11.016.

19.

Comparison of cobas human papillomavirus test results from primary versus secondary vials of PreservCyt specimens and evaluation of potential cross-contamination.

Rao A, Young S, Krevolin M, Sun R, Purner MB, Sharma A, Behrens CM.

Cancer Cytopathol. 2012 Dec 25;120(6):380-9. doi: 10.1002/cncy.21213. Epub 2012 Jun 20.

PMID:
22718678
20.

The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform.

Eder PS, Lou J, Huff J, Macioszek J.

J Clin Virol. 2009 Jul;45 Suppl 1:S85-92. doi: 10.1016/S1386-6532(09)70013-7.

PMID:
19651374
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk